CCLA Investment Management Cuts Stock Holdings in Abbott Laboratories $ABT

CCLA Investment Management decreased its holdings in Abbott Laboratories (NYSE:ABT) by 10.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 845,716 shares of the healthcare product maker’s stock after selling 94,471 shares during the quarter. CCLA Investment Management’s holdings in Abbott Laboratories were worth $105,942,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth $27,000. Cloud Capital Management LLC purchased a new position in Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories in the third quarter valued at about $31,000. Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories in the second quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories in the third quarter valued at about $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.8%

Shares of ABT opened at $103.70 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a 50 day simple moving average of $109.17 and a 200-day simple moving average of $120.35. Abbott Laboratories has a 1-year low of $100.88 and a 1-year high of $139.06. The stock has a market cap of $180.61 billion, a price-to-earnings ratio of 27.88, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Royal Bank Of Canada dropped their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. BTIG Research dropped their price target on Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup dropped their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Piper Sandler dropped their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Finally, Barclays raised their price target on Abbott Laboratories from $142.00 to $144.00 and gave the company an “overweight” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $134.58.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
• Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
• Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
• Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

Insider Activity

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at $4,458,267.34. The trade was a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock worth $353,097 in the last quarter. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.